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Abstract. Background/Aim: The expression of IL-8 and
FGFR has been related to prognosis and pathological
features in renal cell carcinoma. We investigated the
relationship between IL-8 and FGFR and the outcome in
metastatic renal cell carcinoma (mRCC) patients. Materials
and Methods: Clinical data and histological samples of
patients affected by mRCC and treated with targeted agents
were reviewed. The expression of proteins was assessed
using immunohistochemistry. Results: FGFR1, FGFR2, and
IL-8 were found to be expressed in 16%, 30%, and 50% of
cases, respectively. Significant correlations were found
between selected proteins. A lack of expression of FGFR2
and IL8 was found to be correlated with increased
progression-free survival (PFS). The survival rate at 24
months was 44%, 38%, and 79% of those expressing both,
one, or none of the evaluated proteins, respectively
(p=0.047). Conclusion: This analysis found a relationship
between the expression of IL-8 and FGFR2 in mRCC
patients treated with targeted agents. 
Renal cell carcinoma (RCC) is the sixth most common
cancer in men and the eighth in women in the United States,
with an estimated 65,150 new cases and 13,680 deaths
expected to occur this year (1). In Europe, the incidence and
mortality of RCC are estimated to be 71,739 and 31,293
cases per year, respectively (2, 3).
Since vascular endothelial growth factor (VEGF), its
tyrosine kinase receptor (VEGFR), and the mammalian
target of rapamycin (mTOR) serine threonine kinase have
been commonly used as targets for therapies, the survival
rate of metastatic RCC (mRCC) patients has been notably
improved (4). Nevertheless, 20% of patients progress
during first-line treatment and are considered primary
refractory. Based on this evidence, the identification of
predictive factors remains an unmet need for the clinical
management of advanced disease, while available
classifications based on clinical parameters have only a
prognostic role (5). 
Interleukin-8 (IL-8), alternatively known as CXCL8, is a
pro-inflammatory CXC chemokine whose expression has
been shown to be regulated by a number of different stimuli,
including inflammatory signals, chemical and environmental
stresses, and steroid hormones (6). Similarly, fibroblast
growth factor receptors (FGFRs) have been reported to have
a specific role in cell proliferation and migration,
differentiation, apoptosis, survival, epithelial-mesenchymal
transition, and tumorigenesis (7). These factors belong to a
family of four tyrosine kinase receptors and can be activated
by their cognate ligands and by cell adhesion molecules
such as the neural cell adhesion molecule (NCAM) (7).
Both IL-8 and FGFR have been reported to have a
prognostic role in RCC (8, 9), but their relationship has
never been investigated.
In the present study, we aimed to investigate the
correlation between the expression of IL-8 and FGFR and
the predictive role of their combined expression in metastatic
RCC (mRCC) patients treated with targeted agents. 
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Patients and Methods
Patients. We identified, at two University Centers in Italy, all the
patients treated with targeted agents for metastatic disease who had
previously received radical nephrectomy or nephron-sparing surgery
or had undergone a tumor biopsy. All the selected patients were
required to have in their patient file histological samples from their
primary tumors or metastatic sites and adequate clinical information
and follow-up details. All patients gave their written informed
consent and the study received the approval of the Institutional
Review Board and Ethical Committee.
Immunohistochemical staining. Tumor samples were obtained from
formalin-fixed and paraffin-embedded surgical specimens. After
deparaffinization, rehydration, and the blocking of endogenous
peroxidase activity, immunohistochemical staining was performed
using a polyclonal rabbit anti–IL-8 antibody (sc-7922, Santa Cruz
Biotechnology, CA, USA) at a 1:50 dilution, a polyclonal rabbit
anti–FGFR1 antibody (Flg; Santa Cruz Biotechnology) at a 1:200
dilution, a polyclonal rabbit anti–FGFR2 antibody (Bek, Santa Cruz
Biotechnology) at a 1:200 dilution; a secondary antibody; and a
chromogenic substrate (ChromoMap DAB, 760-159 Ventana,
Arizona, USA). The microscopic slides from all the specimens were
reviewed by a urologic pathologist (A.C.) without prior knowledge
of patient outcomes. The percentages of tumor cells that stained
positive for FGFR1, FGFR2, and IL-8 were quantified. Both the
cytoplasmic and membranous staining were scored as 0 (negative),
1 (weakly positive), and 2 (strongly positive). In addition, all cases
with a <5% expression of the marker were considered to be
negative. 
Statistical methods. Comparisons of the pathologic and clinical
features and marker expression were evaluated using the Chi2 test,
T-test, and Wilcoxon test when appropriate. Correlations among the
qualitative variables were evaluated by a Spearman test (rs).
Survival was estimated using the Kaplan–Meier method. The rates
of patients without disease progression at 12 months that were also
alive at 24 months were estimated. The duration of the follow-up
was calculated from the date of first-line treatment to the date of
death or the last follow-up. 
All the statistical analyses were conducted using PASW
(Predictive Analytics SoftWare) (v 21; IBM SPSS), with a 2-sided
p<0.05 considered to be statistically significant.
Results
Overall population. Overall, 36 patients were included in the
final analysis. Sunitinib was the most commonly used first-
line therapy. The main baseline characteristics of the patients
are reported in Table I. The majority of patients were male,
and the median age was 60 years. 42% of them had
metastatic disease at diagnosis, 94% underwent a radical
nephrectomy, and 92% had clear cell histology. Based on
Memorial Sloan Kettering Cancer Center (MSKCC)
prognostic classification, this was good in 30% of cases,
intermediate in 56%, and poor in 14%. The median time
from diagnosis to the start of therapy was 10.1 months
(IQR=1.6-28.0).
At the cut-off date, 30 patients had disease progression
and 25 were deceased. The median follow-up was 54.4
months, the median survival 33.0 months (95%CI=12.0-
54.0), and the median PFS at the time of first-line treatment
11.8 months (95%CI=7.7-16.0). Finally, 28% of patients had
PFS shorter than six months
IL-8. The expression of IL-8 was found to be negative (IL-
8–) in 18 patients (50%) and positive (IL-8+) in the
remaining 18 cases. Among these, the staining was
considered to be 1+ in five (14%) and 2+ in 13 (36%) cases
(Figure 1). No significant differences were found among the
baseline characteristics of patients and the positive or
negative expression of IL-8. 
The rate of patients without disease progression at 12
months was 66% in the IL-8– subjects and 25% in the IL-8+
cases (p=0.022). The rate of patients alive at 24 months was
78% in the IL-8– group and 33% in those who were IL-8+
(p=0.009) (Figure 2).
FGFR1. The expression of FGFR1 was found to be negative
(FGFR1–) in 30 cases (84%), and positive (FGFR1+) in the
remaining six. Among these, the staining was considered to
be 1+ in three cases (8%) and 2+ in the remaining three (8%)
(Figure 1). No significant differences were found among the
baseline characteristics of the patients and the positive or
negative expression of FGFR1. 
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Table I. Main characteristics of patients.
Characteristics                                                         Patients
                                                                                  N=36
Male                                                                    64%
Median age (IQR)                                             60 (52.1-65.8)
Histology                                                               
   Clear cells                                                       92%
   Non -clear cells                                                 8%
Nephrectomy                                                     94%
Metastatic t diagnosis                                        42%
Hb<LLN                                                             47%
LDH>ULN                                                         17%
Karnofsky PS <80%                                          14%
Metastatic sites ≥2                                                 
Prognostic MSKCC group                                     
   Good                                                                30%
   Intermediate                                                   56%
   Poor                                                                14%
First-line therapy                                                   
   Sunitinib                                                          75%
   Pazopanib                                                         8%
   Sorafenib                                                           6%
   Bevacizumab                                                     6%
   Temsirolimus                                                     5%
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Figure 1. Expression and staining score (%) for IL-8 (A), FGFR1 (B) and FGFR2 (C).
Figure 2. Progression-free survival (A) and overall survival (B) based on the expression of IL-8.
The rate of cases without progression at 12 months was
46% in both the FGFR1– and FGFR1+ patients. The rate of
patients alive at 24 months was 53% in the FGFR1– cases
and 67% in the FGFR1+ subjects (p=0.8).
FGFR2. The expression of FGFR2 was found to be negative
(FGFR2–) in 23 cases (64%) and positive (FGFR2+) in the
remaining 13. Among these, the staining was 1+ in two (6%)
and 2+ in 11 (30%) cases (Figure 1). No significant
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Figure 3. Progression-free survival (A) and overall survival (B) based on expression of FGFR2.
Figure 4. Progression-free survival (A) and overall survival (B) based on co-expression of FGFR2 and IL-8.
differences were found among the baseline characteristics of
the patients and the positive or negative expression of
FGFR2. 
The rate of patients without disease progression at 12
months was 60% in the FGFR2– patients and 18% in those
who were FGFR2+ (p=0.015). The rate of patients alive at
24 months was 57% in the FGFR2– and 54% in the FGFR2+
patients (p=0.3) (Figure 3).
Correlations. Among the 18 IL-8+ patients, five were also
FGFR1+ and nine were FGFR2+. Among the 18 IL-8– cases,
only one patient was FGFR1+ and four were FGFR2+.
Significant correlations were found between IL-8 and
FGFR1 (rs=0.30; one-tail p=0.039), IL-8 and FGFR2
(rs=0.29; one-tail p=0.044), and FGFR1 and FGFR2
(rs=0.44; one-tail p=0.004).
In order to investigate the predictive role of IL-8 and
FGFR2, we analyzed the impact of their combined
expression on survival. The rate of patients without disease
progression at 12 months was 16%, 31%, and 78% in those
who expressed both, one, or none of the evaluated factors,
respectively (p=0.012). The rate of patients alive at 24
months was 44%, 38%, and 79% in patients who expressed
both, one, or none of the evaluated proteins, respectively
(p=0.047) (Figure 4). A significant correlation was found
between PFS, that was shorter than six months, and the dual
expression of FGFR2 and IL-8 (rs=0.42; one-tail p=0.005).
Discussion
This analysis reports the predictive role of the dual
expression of IL-8 and FGFR2 in mRCC patients treated
with targeted therapies. The expression of these two proteins
is related to a shorter PFS under treatment with targeted
agents as well as with a trend for shorter overall survival. As
these proteins have been evaluated on tumor tissue from the
primitive tumor, their expression might be related to an
innate resistance to anti-angiogenic agents.
FGFR2 has been previously related to resistance to anti-
angiogenic therapies in an RCC experimental model (10).
Welti and colleagues reported that FGF2 is a potent mediator
of endothelial cell resistance to sunitinib (10). They
demonstrated that FGF2 suppresses sunitinib anti-angiogenic
activity by the direct stimulation of pro-angiogenic signaling
in endothelial cells. Moreover, they showed that sunitinib is
able to inhibit the VEGF-mediated activation of ERK1/2 and
PLCγ, but not the FGF2-mediated activation of ERK1/2 and
PLCγ (10). The same authors confirmed the expression of
FGF2 in both tumor and endothelial cells, suggesting that
FGF2 can potently suppress the anti-angiogenic activity of
sunitinib. 
In the present study, we report that about 30% of our RCC
patients who constitutively expressed FGFR2 and had an
intrinsic resistance to sunitinib and had a shorter PFS,
compared to those with a negative or lower expression of
this protein.
Consistently, Huang et al., reported that the 786-O clear-
cell RCC (ccRCC) cell line expressing high levels of IL-8
was resistant to sunitinib (11). Moreover, they found a higher
plasma level of IL-8 in mice with RCC tumors resistant to
sunitinib. The direct relationship between IL-8 and resistance
to sunitinib was also confirmed by the use of a monoclonal
antibody against IL-8 that reversed this resistance (11).
Similarly, in our study, we were able to confirm that high IL-
8 immunohistochemical expression in human RCC is
correlated to the refractoriness to sunitinib (11).
IL-8 seems to have an interesting modulatory effect on the
response to targeted agents, and two studies have also
investigated IL-8 gene polymorphisms in 397 patients treated
with sunitinib or pazopanib for mRCC (12). It was reported
that the first patients enrolled in the phase II and phase III
pazopanib trials with the 2767TT variant had an inferior PFS
compared with the wild-type AA genotype, with a median
PFS of 27 and 48 weeks, respectively (HR=1.8; 95%CI=1.2-
2.7; p=0.009). Similarly, those with the IL-8-251AA
genotype had inferior median PFS compared to their
counterparts with the wild-type TT genotype (32 vs. 49
weeks; HR=1.7; 95%CI=1.1-2.5; p=0.01). Nevertheless, no
significant relationship was found between the IL-8
genotypes and the response rate to therapy (12). The second
study analyzed 27 single nuclear polymorphisms (SNPs)
within 13 genes using data from mRCC patients treated with
pazopanib in a clinical study and the variants related to the
outcome have been tested in a larger group of mRCC
patients treated with sunitinib or pazopanib. Two IL-8 SNPs
were associated with overall survival (OS) (rs1126647 and
rs4073) and were found to be strongly correlated with each
other. Finally, the rs1126647 genotype was validated using
two datasets and confirmed as an independent prognostic
variant (13).
Although both FGFR and IL-8 have a prognostic role in
RCC and both are related to angiogenesis and tumor
progression, their combined role has been never investigated
in this tumor type. A similar correlation was tested by Giri
and Ittman in tissues from patients affected by prostatic
hyperplasia (14). They found that IL-8 produced by prostatic
epithelial cells can induce FGF2, promoting abnormal
proliferation of the prostatic transition zone that is a critical
event in the pathogenesis of benign prostatic hyperplasia
(14). In experimental models, it was proved that the use of
recombinant IL-8 increased by threefold FGF2 release from
prostatic stromal cells, inducing increased levels of FGF2
mRNA. This relationship has also been proven in human
prostate tissue in vivo (14).
Our study confirms the negative predictive role of the dual
expression of FGF2 and IL-8 in RCC. Main limitations of
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the study are its retrospective nature, the low number of
included cases, and the interval of time from the initial
diagnosis and the start of therapy, that may affect the
expression of the investigated proteins. If validated, these
data may improve the selection of mRCC patients, and
suggest possible targets for treatment. 
FGFR inhibitors have already been tested in unselected
mRCC in at least two large trials. In the GOLD phase III
study, patients previously treated with VEGFR and mTOR
inhibitors were randomized to receive the dual VEGFR and
FGFR inhibitor dovitinib or the standard care of sorafenib,
with a similar outcome reported for both therapies (15).
More recently, another VEGFR/FGFR inhibitor, lenvatinib,
was tested in patients previously treated with VEGFR
inhibitors. Patients were randomized to receive either
lenvatinib plus everolimus, single-agent lenvatinib, or single-
agent everolimus, with a significantly longer PFS reported
in patients treated with lenvatinib plus everolimus compared
to everolimus alone (16). These experiences suggest a way
forward for the use of the FGFR inhibitor in mRCC, but also
highlight the importance of patient selection.
Finally, our study may pave the way for further analyses
in order to improve knowledge on prognostic factors and the
selection of patients in future clinical trials.
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